Wegovy® (semaglutide) oral tablets
Approval Date: Dec 2025
Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in obese adults and overweight adults with at least one weight-related comorbidity. This approval is for a new oral tablet formulation of Wegovy, making it the first orally available GLP-1 medication for obesity.
Saxenda® (liraglutide) injection
Approval Date: Aug 2025
A GLP-1 receptor antagonist, this drug is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or who are overweight with at least one weight-related comorbidity. This is the first generically available GLP-1 receptor agonist for the treatment of obesity.
